Guardant Health develops blood-based liquid biopsy tests for cancer detection, therapy selection, and disease monitoring. Its assays analyze circulating tumor DNA to provide genomic insights without requiring traditional tissue biopsies in many clinical settings. The company serves oncologists, health systems, and biopharma partners seeking non-invasive molecular profiling across advanced and earlier-stage cancer care.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 203.5 | — | -95.2 | — |
| Q2 2025 | 232.1 | — | -99.9 | — |
| Q3 2025 | 265.2 | — | -92.7 | — |
| Q4 2025 | 281.3 | — | -128.5 | — |
| Q1 2026 | 301.7 | 48.3% | -112.1 | — |
| Q2 2026 | 335 | 44.3% | -120.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: TPG Inc. (TPG), Entegris, Inc. (ENTG), Charter Communications, Inc. (CHTR), Genmab A/S (GMAB), Hesai Group (HSAI), MACOM Technology Solutions Holdings, Inc. (MTSI)